#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals (“Enanta”), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate. EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has…

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

£16.8m full-service RSV contract with top five global pharma client Highlights · Pharma client is funding expedited manufacture of additional supply of RSV challenge agent · Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch · Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate · Trading ahead of previous market expectations driven by margin expansion hVIVO plc (AIM & Euronext: HVO), the world leader in testing…

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Pneumagen, a clinical-stage biotech company, reporting successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil, demonstrated from a Phase 2a influenza human challenge study conducted by hVIVO. The randomised, double-blind, placebo-controlled study enrolled 104 healthy adult volunteers, recruited through the FluCamp platform, and evaluated two dose regimens…

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Cidara Therapeutics, Inc. (“Cidara”), reporting positive interim results from an ongoing human challenge study testing CD388. hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model. CD388 is…

#ORPH Open Orphan PLC – Positive results from RSV Human Challenge Study February 17, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated February 17 2022 from Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, on positive results from a human challenge study assessing its respiratory syncytial virus (“RSV”) antiviral candidate, EDP-938. The results…

#ORPH Open Orphan – New Malaria Human Challenge Model Launched January 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement on 9 August 2021, hVIVO, a subsidiary of Open Orphan, has inoculated the first cohort of volunteers with a GMP-manufactured malaria challenge agent as part of its first controlled human malaria infection (CHMI) challenge study. This study will assess CHMI using existing standard of…

Experts seek approval for COVID-19 trials – China Daily June 12, 2020 – Posted in: Open Orphan (ORPH)

By ANGUS McNEICE in London Medical community divided on issue of exposing humans to deadly virus A laboratory in the United Kingdom is hoping to become the first in the world to intentionally infect volunteers with novel coronavirus in order to test the efficacy of COVID-19 vaccines. Half of the participants in these so-called human challenge trials would be given a candidate vaccine for COVID-19, the other half would get a placebo, and all of…

#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

#ORPH Open Orphan PLC – Positive results from RSV Human Challenge Study February 17, 2022 – Posted in: Blog, Open Orphan (ORPH)

#ORPH Open Orphan – New Malaria Human Challenge Model Launched January 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Experts seek approval for COVID-19 trials – China Daily June 12, 2020 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL